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Abstract  
There is an accumulating evidence for an increased prevalence of metabolic syndrome 
(MetS) in bipolar patients which is comparable to the prevalence of MetS in patients 
with schizophrenia. Hyperhomocysteinemia has emerged as an independent and 
graded risk factor for the development of cardiovascular disease (CVD) which is at 
the same time, the primary clinical outcome of MetS. The aim of this study was to 
ascertain if the presence of MetS was associated with hyperhomocysteinemia in 
patients with bipolar disorder (N=36) and schizophrenia (N=46) treated with second 
generation antipsychotics (SGA). MetS was defined according to NCEP ATP-III 
criteria and the cut-off point for hyperhomocysteinemia was set up at 15 μmol/L. 
Results of the study indicated that the presence of the MetS is statistically 
significantly associated with the elevated serum homocysteine in all participants. 
Since hyperhomocysteinemia has emerged as an independent risk factor for 
psychiatric disorder and CVD, it could be useful to include fasting homocysteine 
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serum determination in diagnostic panels of psychiatric patients in order to obtain a 
better assessment of their metabolic risk profile. 
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1. Introduction  
There is an accumulating evidence for an increased prevalence of metabolic syndrome 
(MetS) or its modal subcomponents in bipolar patients (Fagiollini et al., 2005; 
Cardenas et al., 2008; Vuksan-Ćusa et al., 2009) which is comparable to (Birkenaes et 
al., 2007; Corell et al., 2008), or even higher (Kilbourne et al., 2007) than the 
prevalence of MetS in patients with schizophrenia. Homocysteine is non-protein 
amino acid that occurs in human by the demetilation of nutritional methionine, 
catalyzed by methyltransferases (Reif et al., 2005). 
There are different genetic-nutrient interactions that can predispose an individual to 
hyperhomocysteinemia (Cortese and Motti, 2001; Carmel et al., 2003). 
Most cases of mild hyperhomocysteinemia are due to the nutritional folate and 
vitamin B12 deficiency and/or reduced glomerular filtration rate, while in severe 
cases mutations in key enzyme of homocysteine metabolism-
methylentetrahydrofolatreductase (MTHFR) can be found (Feng et al.,2009). It is well 
known that several widely used drugs, such as lipid-lowering drugs (like fibrates and 
niacin) or oral hypoglycemic drugs (like metformin), insulin, drugs used in 
rheumatoid arthritis (corticosteroids and non-steroidal antinflammatory drugs) and 
anticonvulsants (carbamazepine, phenytoin, phenobarbital) can cause elevated 
homocysteine concentrations (Dierkes and Westphal, 2005). 
Hyperhomocysteinemia has emerged as an independent and graded risk factor for the 
development of cardiovascular disease (CVD) (Mangoni and Jackson, 2002) which is, 
at the same time, the primary clinical outcome of the MetS (Ninomiya et al., 2004). 
Elevated level of serum homocysteine is a risk factor for several diseases of central 
nervous system (Herrman et al., 2007; Stanger et al., 2009). Hyperhomocysteinemia 
has been found in young male schizophrenia patients (Levine et al., 2005) and bipolar 
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patients showing functional and cognitive deterioration (Osher et al., 2004, Dittman et 
al., 2007, Dittman et al., 2008). The role of elevated levels of homocysteine in 
psychotic disorders could be explained with partial antagonism on NMDA-glycine 
site (Neeman et al., 2005), which may contribute to symptom development. Further 
more, some authors (Gilbody et al., 2007; Ozbek et al., 2008) emphasized that high 
homocysteine and low folate and vitamin B12 levels may be independent risk factors 
for development of schizophrenia and bipolar disorder and that folate supplementation 
could possibly play a protective role in the development of schizophrenia and bipolar 
disorder when taken during pregnancy.  
The association between homocysteine levels and MetS in psychiatric patients is not 
well characterized. Previous study (Garcin et al., 2006) showed that 
hyperhomocysteinemia is not associated with the MetS in non-psychiatric male 
population, but it is weakly correlated with systolic and diastolic blood pressure, 
creatinine clearance, tobacco use, cholesterolemia, tryglycerides and free fatty acids. 
On the other hand, results from recent studies confirmed association between MetS 
(and/or hyperlipidaemia, especially low HDL-c) and hyperhomocysteinemia in 
patients with CVD showing that MetS and hyperhomocysteinemia could work 
together in increasing CVD risk (Bellia et al., 2007; Obeid and Herrman, 2007). 
The aim of this study was to ascertain if the presence of MetS was associated with 
hyperhomocysteinemia in patients with bipolar disorder and schizophrenia.   
Additionally we investigated if there were differences in the prevalence of metabolic 
syndrome and homocysteine levels in patients with bipolar disorder and schizophrenia 
treated with SGA.  
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2. Methods 
 
2.1. Sample 
 
Subjects were consecutively admitted inpatients with bipolar disorder (N=36, 20 
males and 16 females) and schizophrenia (N=43, 30 males and 16 females) treated 
with SGA at the Department of Psychiatry, University Hospital Centre Zagreb during 
the period of 36 months.   
The diagnosis of bipolar disorder and schizophrenia was made according to diagnostic 
criteria of the International Statistical Classification of Diseases and Related Health 
Problems, 10th Revision (ICD-10), (WHO, 1996).   
Intensity of depressive symptoms in bipolar patients was assessed by Hamilton 
Depression Rating Scale, HDRS-17 (Hamilton, 1960), while manic symptoms were 
assessed by Young Mania Rating Scale, YMRS (Young et al., 1978). The intensity of 
psychotic symptoms of schizophrenia patients was assessed by PANSS (Kay et al., 
1987). All bipolar patients who entered the study were in at least one month euthymic 
phase defined with HAMD-17 score 7 or less and YMRS score 5 or less in order to 
eliminate the possible influence of the depressive or manic episode on serum 
homocysteine levels and metabolic parameters. The most recent episode in 19 bipolar 
patients was manic and in 17 patients was depressive episode. All patients with 
schizophrenia were in a stable phase which means that pharmacotherapy was not 
changed within a month. A trained psychiatrist performed clinical evaluation. 89% of 
bipolar patients and 22% of schizophrenia patients were concomitantly treated with 
mood stabilizers. 
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The exclusion criteria were: hypertension, diabetes mellitus, inherited disorders of 
lipoprotein metabolism, diagnosis of substance abuse, including alcoholism, eating 
disorder, epilepsy, organic brain syndrome, pregnancy, lactation and use of B-
vitamins and carbamazepine.  
Written informed consent was obtained from all participants, under procedures 
approved by the Local Ethics Committee and in accordance with the Helsinki 
Declaration. 
 
2.2. Assessment         
Venipuncture was performed for all subjects between 8 and 9 a.m. after 12 hours 
overnight fast. Immediately after collecting blood samples, serum concentration of 
total cholesterol, high density lipoprotein cholesterol (HDL-c), low density 
lipoprotein cholesterol (LDL-c), triglycerides and serum glucose were determined 
using enzyme methods and commercial kits (Olympus Diagnostic, GmbH, Hamburg, 
Germany) on Olympus AU 600 automated analyzer. Inter- assay laboratory 
coefficients of variation were 3.2% for cholesterol, 2.5 for triglycerides and 3.0% for 
HDL- cholesterol. Reference intervals for the measured parameters were as follows: 
cholesterol <5.0 mmol /L, LDL <3.0 mmol /L, HDL>1.0 mmol/L, triglycerides <1.7 
mmol/L and glucose >6.1 mmol/L. Total homocysteine serum levels were determined 
using capillary gas chromatography-mass spectrometry (Stabler et al., 1987). The cut-
off point for homocysteine elevation was set at 15 μ mol/L according to the reference 
of our laboratory and the data from the literature (Hirsch et al., 2004; To-Figueras et 
al., 2010). Since it is documented that erythrocytes continue to produce and export 
homocysteine into the plasma after the venipuncture (Calam et al., 2005) the collected 
specimens are placed in tubes containing EDTA, kept on on ice  and centrifuged 
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within one hour  after collecting the blood in order to avoid artifactual increase of 
homocysteine.  
Height and weight of each patient were recorded while they were standing barefoot in 
light clothes on the medical scale that measures height and weight. Body mass index 
(BMI) was calculated that body weight in kilograms was divided with squared height 
value in meters. Waist circumference, which is considered an accurate estimate of 
visceral adiposity, was measured at minimal respiration at high point of the iliac crest 
and at the level of umbilicus. Sitting blood pressure was measured in subjects after 
they were interviewed in the sitting position for about 5 min while discussing neutral 
topics. 
MetS was defined according to NCEP ATP III criteria (Expert panel JAMA, 2001). 
The presence of 3 or more of the following criteria was required to meet criteria for 
MetS: 
1. abdominal obesity:waist circumference >102 cm in men and >88 in woman 
2. hypertrigliceridemia :≥1.7 mmol/L 
3. low HDL-cholesterol:<1.04 mmol/L in men and <1.29mmol/L in woman; 
4. high blood pressure:≥ 135/85 mm Hg; 
5. high fasting glucose:≥6.1 mmol/L   
 
2.3. Data analysis 
Baseline characteristics were compared by t-test for independent samples or 
nonparametric Mann-Whitney test when variable was not normally distributed, when 
comparing 2 groups. For categorical variables chi-square test was used, or Fisher’s 
exact test for 2x2 contingency tables. As measures of association between variables 
Contingency coefficient for categorical and Spearman coefficient of correlation for 
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continuous asymmetrically distributed variables were used. Analyses were done using 
SPSS for Windows Version 13.0. Probability level of p<0.05 was considered to be 
statistically significant. 
 
3. Results 
Results of the study showing differences in demographic, biological and clinical 
parameters between bipolar disorder and schizophrenia patients are presented in Table 
1 and Table 2. 
For bipolar patients mean HAMD-17 score was 5.7±1.1, mean YMRS score 4.1±1.7, 
and mean PANSS score for patients with schizophrenia was 68±15.19.  
In our whole sample (BAP+sch) 27(34.2%) patients had MetS. 
Regarding gender effect on the prevalence of MetS results indicated that there were 
no difference between male and female in a whole sample (χ²=3.134, p=0.089, df=1). 
Results of the study showed higher proportions of hyperhomocysteinemia in males in 
both groups (35% M, 17% F in bipolar group, 29% M, 20% F in schizophrenia 
group), but without reaching statistical significance. 
Presence of the MetS is statistically significantly associated with the elevated serum 
homocysteine in all participants (Mann Whitney U = 484.500, p<0.001). 67% 
participants in whole sample with hyperhomocysteinemia had fulfilled criteria for 
MetS, while only 23% participants without hyperhomocysteinemia had MetS 
(p<0.001). When bipolar and schizophrenia group are taken separately, there is 
statistically significant association within both groups (r=0.40, p=0.005; r=0.36, 
p=0.021) respectively. 
Serum homocysteine significantly correlated with systolic (r=0.30, p<0.01) and 
diastolic blood pressure (r=0.25, p<0.05) in all participants. Looking at bipolar and 
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schizophrenia patients separately, this association between homocysteine and systolic 
(r=0.30), as well for diastolic pressure (r=0.27) remained statistically significant (for 
both p<0.05). There were no significant correlations between other subcomponents of 
MetS and serum homocysteine. 
4. Disscusion  
Although in the past years more attention has been devoted to the medical burden 
suffered by patients with schizophrenia, recently similar concern has arisen for bipolar 
disorder patients. Our results showed that the prevalence of MetS in bipolar disorder 
(31%) is comparable to the prevalence of MetS in schizophrenia (37%), thus 
confirming the results from the study of Corell et al. (2008). These findings suggest a 
shared susceptibility of psychiatric patients to metabolic dysregulations that is not 
primarily related to specific psychiatric diagnosis. 
Knowing that MetS represents a major risk factor for the development of CVD, 
gender differences in this syndrome may contribute to gender differences in CVD. In 
recent years, MetS has been more prevalent in men than in women (Regitz-Zagrosek 
et al., 2010), although other authors found that MetS affects Caucasian men and 
women roughly equally (Gupta and Gupta, 2010). Prevalence is increasing in general 
and this increase has been steeper in woman, particularly in young woman during the 
last decade (Regitz-Zagrosek et al., 2006), where it is mainly driven by obesity. In our 
sample we did not discover gender differences in the prevalence of MetS in patients 
with bipolar disorder and schizophrenia which is in line with the results from the 
study of Bobes et al., (2010). 
The mean homocysteine level for schizophrenia patients in our study was 
11.1±5.1μmol/l which was very similar to the results (11.6±5.8) from the study of 
Reif et al., (2005). For our bipolar patients mean homocysteinemia was 
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14.0±11.9μmol/l which was somewhat higher than in above mentioned study 
(12.9±3.8μmol/l ), possibly because the examined group in that study consisted of 
bipolar and unipolar depressive patients. As it can be seen, there is a trend of higher 
homocysteine level in affective disorder than in schizophrenia, although our results 
did not reach statistical significance. However, it is noteworthy that, in our study, 
mean values of serum homocysteine in both groups were lower than 15 μmol /L 
which is a cut-off point for hyperhomocysteinemia.  
In contrast to previous studies (Applebaum et al., 2004; Levine et al., 2002, 2005; 
Reif et al., 2005) in which homocysteine level was found to be higher in males, we 
could not detect gender-specific differences for homocysteine in patients with bipolar 
disorder and schizophrenia.   
Since 67% participants with elevated serum homocysteine levels had fulfilled criteria 
for MetS and only 23% participants with normal levels of serum homocysteine levels 
had MetS we can hypothesize that elevated serum homocysteine levels could be 
associated with metabolic impairments typically observed in MetS. Previous studies 
showed inconsistent results regarding association between MetS and 
hyperhomocyteinemia in relation with CVD (Garcin et al., 2006; Bellia et al., 2007). 
In the second study authors found co-existence of hyperhomocysteinemia and 
metabolic syndrome in 67.2% CVD patients suggesting that the presence of two 
conditions gives rise to stronger increase in CVD risk. 
To our knowledge, this is the first study examining the association between MetS and 
homocysteine levels in psychiatric patients. Previous studies explored homocysteine 
and some metabolic parameters, but not the complete syndrome. The study from 
Assies and al. (2004) found an association between omega 6-fatty acids and 
homocysteine levels in patients with major depression. Another study showed 
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significant correlation between homocysteine levels and BMI, triglycerides and HDL 
in patients with schizophrenia (Akanji et al., 2007). 
Since our results suggest association between hyperhomocysteinemia and MetS in 
bipolar and schizophrenia patient, they can indicate the usefulness of including fasting 
homocysteinemia determination in diagnostic panels of psychiatric patients in order to 
obtain better assessments of their metabolic risk profile. These findings emphasize the 
need to develop strategies for controlling the MetS and its components as well as 
homocysteine levels. Since most cases of mild hyperhomocysteinemia is due to the 
nutritional folate and vitamin B12 deficiency, this could be of significant clinical 
importance because most studies showed that vitamin B supplementation can lower 
homocysteine levels (Lonn et al., 2006; Herrmann et al., 2007).  
Limitations of the study regard to small sample size, lack of healthy controls and its 
cross-sectional design does not allow causal relations. Due to small sample results are 
only preliminary and further investigations are needed. Also, there was no data on 
physical activity, smoking, coffee consumption and dietary habits (daily intake of 
folate and vitamin B12) which may all influence homocysteinemia. We did not 
measure vitamin B12 and folate serum levels and these measurements should be 
included in future studies. It is important to note that our patients were not drug free 
since many drugs can cause homocysteine elevation.The findings from the literature 
regarding the role of SGA in homocysteine levels are scarce and conflicting. It has 
been reported that psychotic patients treated with SGA had higher homocysteine than 
healthy controls and that antipsychotic medication type had no significant effect on 
absolute levels of homocysteine (Neeman et al., 2005), but the results from another 
study (Sarandol et al., 2007) showed no differences in homocysteine levels between 
theese two groups.Bipolar patients were significantly older than patients with 
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schizophrenia, probably due to the the delay in diagnosing, which could also influence 
the results since homocysteine levels and the risk of MetS increase with age.   
In conclusion, our results suggest strong association between hyperhomocisteinemia 
and MetS in patients with psychotic disorders. It could be useful to include fasting 
homocysteinemia determination in diagnostic panels of psychiatric patients in order to 
obtain a better assessment of their metabolic risk profile. 
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